

ANALISIS KADAR IFN- γ dan IL-10 SEBAGAI PENANDA INFLAMASI DAN RESPONS TERAPI OBAT ANTI TUBERKULOSIS PASIEN TB PARU MDR

by Herni Setyawati

Submission date: 15-Nov-2019 04:02PM (UTC+0800)

Submission ID: 1214335117

File name: AN_RESPONS_TERAPI_OBAT_ANTI_TUBERKULOSIS_PASIEN_TB_PARU_MDR.docx (363.45K)

Word count: 4040

Character count: 22048

Penelitian

**ANALISIS ¹KADAR IFN- γ dan IL-10 SEBAGAI PENANDA INFLAMASI DAN
RESPONS TERAPI OBAT ANTI TUBERKULOSIS PASIEN
TB PARU MDR**

Oleh:
Herni Setyawati
Soedarsono
Yulistiani
Umi Fatmawati

Herni Setyawati, S.Si, Apt
Magister Farmasi Klinik, Fakultas Farmasi Universitas Airlangga, Surabaya, Indonesia
Jalan Ketintang Wiyata No 38 Surabaya, Jatim, Indonesia
hernisetyawati285@gmail.com
Hp: 081329502427

ABSTRAK

ANALISIS KADAR IFN- γ dan IL-10 SEBAGAI PENANDA INFLAMASI DAN RESPON TERAPI OBAT ANTI TUBERKULOSIS PASIEN TB PARU MDR

(Penelitian di Poliklinik MDR TB RSUD Dr. Soetomo Surabaya)

Herni Setyawati¹, Soedarsono², Yulistiani³, Umi Fatmawati⁴

¹ Master Program of Clinical Pharmacy, Universitas Airlangga;

² Department of Clinical Pharmacy, Faculty of Pharmacy, Airlangga University;

³ Department of Pulmonology, Faculty of Medicine, Airlangga University, Dr. Soetomo Teaching Hospital, Surabaya

⁴ Department of Pharmacy, Dr. Soetomo Teaching Hospital, Surabaya

Latar Belakang: Multidrug Resistant Tuberculosis (MDR TB) disebabkan oleh organisme yang resisten terhadap paling sedikit isoniazid dan rifampisin, dua obat TB yang paling manjur. Respon kekebalan terhadap infeksi *Mycobacterium tuberculosis* berhubungan dengan fungsi imunitas. Fungsi interferon- γ (pro-inflamasi) adalah mengaktifkan makrofag, untuk merangsang molekul antimikroba (untuk spesies oksigen reaktif dan oksida nitrat), dan untuk menghambat interleukin-10. Fungsi interleukin-10 adalah untuk memicu kekebalan humoral, untuk menghambat IFN- γ .

Tujuan: penelitian ini bertujuan untuk menganalisis kadar IFN- γ , IL-10 dan data klinis terhadap pasien TB-MDR yang mendapat terapi standar OAT.

Metode: observasional, desain cross sectional. Terdapat 29 pasien yang mendapat terapi standar MDR TB OAT dari 1-24 bulan, yang memenuhi kriteria inklusi. Kemudian, pasien dibagi berdasarkan durasi terapi, yaitu fase awal / intensif dan lanjut. Tahap awal dibagi menjadi 2: yaitu terapi 1-4 bulan (5 pasien) dan lebih dari 4-8 bulan (6 pasien). Kemudian, tahap lanjutan dibagi menjadi dua kelompok, yaitu kelompok ketiga > 8-16 bulan (13 pasien) dan kelompok > 16-24 bulan (5 pasien). Kemudian, diukur konsentrasi serum IFN- γ , IL-10 pada tahap awal penelitian dan 4 minggu kemudian dengan metode ELISA. Penelitian ini berlangsung selama periode Juli-Desember (6 bulan).

Hasil: Konsentrasi pasca IFN-rations menurun sebesar $39,14 \pm 139,12$ pg / mL ($p > 0,05$). Konsentrasi IL-10 menurun sebesar $33,93 \pm 109,20$ pg / mL ($p > 0,05$). Berdasarkan metode bandim TB skor selama pra dan hasil posting adalah 1 pasien mengalami perubahan keparahan dari tingkat keparahan kelas 1 sampai 2, 1 pasien dari tingkat keparahan kelas 2 sampai 1, 1 pasien tetap dalam tingkat keparahan 2 dan 26 pasien tetap dalam tingkat keparahan 1.

Kesimpulan: Tidak terjadi perubahan kadar IFN- γ dan IL-10 setelah 4 minggu pasca terapi OAT standar TB MDR pada tahap awal terapi dan tahap lanjutan

Kata kunci: IFN- γ , IL-10, TB MDR, pre-post

1
ABSTRACT

**ANALYSIS OF IFN- γ AND IL-10 LEVELS
AS INFLAMMATORY MARKERS AND THERAPEUTICAL RESPONSE OF
ANTI-TUBERCULOSIS IN MDR TB PATIENTS**

(The research at Polyclinic MDR TB RSUD Dr. Soetomo Hospital Surabaya)
Herni Setyawati¹, Soedarsono², Yulistiani³, Umi Fatmawati⁴

¹ Master Program of Clinical Pharmacy, Universitas Airlangga;

² Department of Clinical Pharmacy, Faculty of Pharmacy, Airlangga University;

³ Department of Pulmonology, Faculty of Medicine, Airlangga University, Dr. Soetomo Teaching Hospital, Surabaya

⁴ Department of Pharmacy, Dr. Soetomo Teaching Hospital, Surabaya

Background: *Multidrug-Resistant Tuberculosis* (MDR TB) is caused by a organism that is resistant to at least isoniazid and rifampicin, the two most potent TB drug. Immune response to against *Mycobacterium tuberculosis* infection is related to the function of immunity. The function of interferon- γ (pro-inflammatory) is to activate macrophages, to stimulate antimicrobial molecules (to reactive oxygen species and nitric oxide), and to inhibits interleukin-10. Interleukin-10 function is to triggers humoral immunity, to inhibit IFN- γ .

Objective: this study aimed to analyze level changes and the correlation with clinical data, also months of MDR TB patients who received standard OAT therapy.

Methods: observational, cross sectional design. There were 29 patients who received standard MDR TB OAT therapy from 1-24 months, who met the inclusion criteria. Then, the patients were divided based on duration of the therapy, which are the initial/intensive and advanced phase. The initial phase divided into 2: first one is for 1-4 months therapy's time (5 patients) and the second one is for more than 4-8 months (6 patients). Then, the advanced group divided into two groups again, which are third group with more than 8-16 months (13 patients) and fourth group with more than 16-24 months (5 patients). Then, measured serum concentration IFN- γ , IL-10 at the start of the study and 4 weeks later with the ELISA method. This research during the period July-December (6 months).

Results: IFN- γ post concentrations were decreased by 39.14 ± 139.12 pg/mL ($p > 0.05$). The concentration of IL-10 was decreased by 33.93 ± 109.20 pg / mL ($p > 0.05$). Based on the TB score bandim method during pre and posts results were 1 patient experienced severity change from severity class 1 to 2, 1 patient from severity class 2 to 1, 1 patient remained in severity 2 and 26 patient remained in severity 1.

Conclusions: The results showed that serum IFN- γ and IL-10 levels in initial/intensive and advanced phase patients who received MDR TB regimen after four weeks did not changed.

Keyword: IFN- γ , IL-10, TB MDR, pre-post

INTRODUCTION

¹ MDR-TB is TB caused by *Mycobacterium tuberculosis* that already resistant to at least two of most effective antituberculosis agents (ATA), isoniazid dan riphampicin. (Mase, 2013). MDR-TB regimens are more complex, less effective, more toxic and using more combination of ATA in longer periode (Antonio, Lemoa, & Matos, 2013).

Sputum conversion of mycobacterial from positive to negative in tuberculosis patients are considered as important indicator for pharmacological effects of ATA in MDR-TB patients (Holtz, et al., 2006). Sputum conversion generally occurs in the second month of treatment and is said to be negative if two months later gives a negative sequence. Differences in sputum conversion time can consequence to difference in therapy outcomes of patients despite they receiving the same regimen. It may caused by different immune responses of the patient, eventhought severity of the disease is also determined by the virulence factor of the bacteria, nutritional status and host genetic factors (Adrian, Montiel, Fernandez, & Valecillo, 2015). The hosts immunity against tuberculosis bacteria is mediated by the presence of cellular immunity, ie, certain cytokines and ²⁵ T helper cells (Th cells) that play an important role (Kinjo, et al., 2002).

Those cytokines include IFN- γ and ¹⁴ IL-10. IL-10 is an anti-inflammatory cytokine that ² inhibit T lymphocytes and also inhibit Th1 and Th2. IL-10 acts to inhibit the production of cytokines proinflammatory (IFN- γ , TNF- α and IL-12) and antigen presenting cell, inhibiting the activity of T lymphocytes by inhibition of molecular expression of MHC II. Therefore IL-10 is an important cytokine because it has an immunoregulatory function to establish a balance between proinflammatory and anti-inflammatory cytokines (Adrian, Montiel, Fernandez, & Valecillo, 2015).

IFN- γ is a major cytokine that activates macrophages, stimulates the production of antimicrobial molecules (osygen reactive species and nitric oxide) in process of *Mycobacterium tuberculosis* elimination, and stimulates ³¹ immune cells migration to the area

of infection (Cavalcanti, et al., 2012, Goldsack & Kirman, 2007). It also contributes to granuloma formation to inhibit the progression of TB (Ali Khan, et al., 2016). Several studies IFN γ and IL-10 indicates various effect and outcomes.

Based on the above description, it is important to do this study. Some study showed existed relationship between ¹⁹ levels of cytokines IFN- γ and IL-10 in the body with TB progression and ATA outcome (Clifford, et al., 2015). The combination of those immunologic and clinical markers is expected to predict bacterial progression through proinflammatory and antiinflammatory activity balance, which can prevent relapse after therapy and reduce treatment duration (Waalzl, Ronacher, Hanekom, & Scriba, 2011, Clifford, et al., 2015) This study is expected to provide an overview or ³² profile of proinflammatory and antiinflammatory cytokines levels in patients with pulmonary MDR-TB and can be used as a proposed marker to predict treatment outcome and the prognosis of pulmonary MDR-TB.

METHODS

²⁴ This study was an observational (non experimental) analytic study, with cross sectional design. The independent variables are the stage of therapy while the dependent variables are serum levels of IFN- γ , and IL-10. Each phase are divided into 2 groups based on the duration of therapy such as initial phase : group 1 (duration of 1-4 months), group 2 (duration of therapy 4-8 months), and continuation phase : group 3 (therapy 8-16 months) and group 4 (therapy 16-24 months).

The sample of this study was ⁷ patients with pulmonary MDR-TB who fulfilled the inclusion criteria: MDR patients aged 15-64 years old, received standard ATA in TB MDR regimen, able to take oral and or enteral and willing to be the subject of this study. Exclusion criteria included patients with HIV test positive, pediatric patients, geriatrics, pregnant and / or breast-feeding women, history of autoimmune diseases and using corticosteroids or other

immunosuppressants. The study was conducted in July-December 2017 at TB-MDR units of Soetomo Teaching Hospital Surabaya Indonesia.

Sample of this study were counted using below formulation:

$$n = \frac{z_{1-\alpha/2}^2 P(1-P)N}{d^2(N-1) + z_{1-\alpha/2}^2 P(1-P)}$$

where: $1-\alpha$ = confidential intervaltingkatkepercayaan (95%)

$$Z_{1-\alpha/2} = 1,96$$

P = anticipated pulation proportion (0,50)

d = absolute precession neede (0,15)

N = total population (55)

Using thi formulation, we obtained that total sample minimum are 25 patientse. Sampling technique used in this study are consecutive sampling method, we got total sample of 29 patients

This study has approved by the Ethics Committee of Soetomo Teaching Hospital Surabaya. All patients included in this study has sign their agrement in an inform concerned form. Blood serum of patients who met the inclusion criteria were taken and examined their levels of IFN- γ , and IL-10 twice, at the start of this study and four weeks after the first blood count. IFN- γ , and IL-10 levels were measured using ELISA techniques. To determine the difference between IFN- γ and IL-10 pre and post profiles, we use Paired T-test statistical methods was used when the data was normally distributed ($p > 0.05$), or wilcoxon test non normally distributed data ($p < 0.05$).

RESULTS

In this study, total of 29 patients met the inclusion criteria. Baseline characteristics of patients included in this study shown in table 1:

Table 1. Baseline characteristics of patients

Patients characteristic		Total Patients	%
Sex	Male	19	65,52%
	Female	10	34,48%
Ages	(15-24) years	3	10,34%
	(25-34) years	4	13,79%
	(35-44) years	9	31,03%
	(45-54) years	8	27,59%
	(55-65) years	5	17,24%
Sputum conversion	Not converted after 4 months	4	13,79%
	1 months	3	10,34%
	2 months	13	44,83%
	3 months	6	20,69%
	4 months	3	10,34%
Resistance	H, R	12	41,38%
	H, R, E	8	27,59%
	H, R, S	6	20,69%
	H, R, E, S	3	10,34%
Initial phase regimens			
	E, Km, Lfx, Eto, Cs, B6	4	41,38%
	Z, E, Cm, Lfx, Eto, Cs, B6	6	48,28%
	Z, Cm, Lfx, Eto, Cs, B6	1	6,90%
Continuation phase regimen			
	Mfx, Eto, Cs, B6	1	3,45%
	Z, Lfx, PAS, B6	1	3,45%
	Z, Lfx, Eto, Cs, B6	3	10,34%
	Z, E, Mfx, Eto, Cs, B6	1	3,45%
	Z, E, Lfx, Eto, Cs, B6	12	41,38%
Duration of therapy			
	1-4 months	5	17,24%
	(>4-8) months	6	20,69%
	(>8-16) months	13	44,83%
	(>16-24) months	5	17,24%
Comorbid			
	DM Type 2	14	48,28%
	DM 2 + Hepatitis	1	3,45%
	No comorbid	14	48,28%
Patient compliance during the study			
	> 80%	24	82,76%
	(60-80)	3	10,34%
	< 60%	2	6,90%
Patient compliance during treatment			
	> 80%	25	86,2%
	(60-80)	3	10,3%
	< 60%	1	3,5%

Table 1. Baseline characteristics of patients

Patients characteristic	Total Patients	(%)
Patients history		
Relaps	10	34,48%
New cases	1	3,45%
Therapy failed	2	6,9%
Drop out	16	55,17%
BMI (Body Mass Index)		
$\geq 18\text{kg/m}^2$	18	62,07%
16-18kg/m ²	7	24,14%
$< 16\text{kg/m}^2$	4	13,79%

First, IFN- γ and IL-10 levels are determined by making a standard curve of each markers and then followed by measured their absorbance using ELISA. Profile of IFN- γ and IL-10 levels (averages) and their statistics result are shown in Figure 1. Its shows that there were no significant difference in averages levels of those markers ($p > 0.05$).




Figure 1. Serum level average of IFN- γ (a) and IL-10 (b) before and after 4 weeks measurements

Figure 1 shows profile of IFN- γ and IL-10 levels (averages) before and after 4 weeks measurements in every groups of patients. Figure 2 showed that there were increasing of serum levels of IFN- γ and IL-10 between group 1 (1-4 months) and groups 2 (4-8 months). This levels are decrease in patients who were in groups 3 and then increased in group 4. Meanwhile, serum levels of IFN- γ and IL-10 are increased after 4 weeks measurements in

group 1, while in group 2 and group 3 the serum level were elevated. Serum levels of IFN- γ in patients in group 4 were slightly increased while their serum levels of IL-10 are decreased.

None of those are statistically significant




Figure 2. Serum level average of IFN- γ (a) and IL-10 (b) before and after 4 weeks measurements in each groups of patients

Figure 3 shows that the serum levels of IFN- γ and IL-10 were tend to increase based on the duration of ATA therapy, while the trendline (trend curve) of serum levels of IFN- γ and IL-10 after 4 weeks of pre measurement are lower than their pre-levels but still tend increase.

Figure 4 shows trendline of difference/changing of serum levels of IFN- γ and IL-10 before starting this study and after 4 weeks of MDR TB regimens. It shows that there were a trendline of plateau (non changing) in serum levels of IFN- γ , where serum levels of IL-10 are tends to decrease.




Figure 3. Trendline of serum level average of IFN- γ (a), IL-10 (b) before and after 4 weeks measurements




Figure 4. Trendline of serum level changing (delta) of IFN- γ (a) and IL-10 (b) before and after 4 weeks measurements

DISCUSSION

In our study, our subject are patients who using MDR-TB regimen of second-line anti-tuberculosis agnts (ATA) in accordance with ministry of health guideline. In the initiation or intensive phase, MDR-TB regimens are aimed to inhibit the replication of mycobacteria while the continuation phase are aimed to fight persistent bacteria (Jain S, 2008). Based on

Figure 1, serum levels of IFN- γ (proinflammatory) and IL-10 (anti-inflammatory) are not significantly decreased ($p > 0.05$) between pre and after 4 weeks of measurement.

Figure 2 shows that the serum levels of IFN- γ and IL-10 at the initial phase of MDR-TB regimens was increased eventhought not statistically significant ($p > 0.05$). This may caused by patient's condition were on the transition stage to conver from smear positive to negative. In this phase, the condition of inflammation can not be controlled or immune response to remove T cell are not adequate. BTA is still positive indicating the occurrence of replication of *Mycobacterium* that can not be eliminated by macrophages. Mycobacterium subsequently interacts with CD4 lymphocytes T cells and releases proinflammatory cytokines. We assumed this is the reason why serum levels of both markers are increased in the early phase. Normally, it takes about 3 weeks after infection before T-helper 1 (Th1) responds by activating macrophages to enhance the bactericidal effect (Jain S, 2008).

In addition, various literature states the occurrence of drug side effects in the early stages of therapy. The occurrence of side effects of the drug will affect the adherence of drug use. So that in case of drug discontinuation will unilaterally affect the level of cytokines. Gastrointestinal side-related side effects are most common and this often results in treatment changes (Shin, et al., 2007). Suspected agents for side effects of nausea and vomiting are pyrazinamide, etionamide and PAS (Reviono, et al., 2014). Ototoxicity may be caused by capreomycin and kanamycin. Patients with DM type 2 comorbidities whose blood sugar are uncontrolled will consequence on increasing of extracellular osmosis pressure increases, the cells are dehydrated so that phagocytosis are decreased followed by penetration of germs intracellular and necrosis occurs. (Mihardja, Lolong, & Ghani, 2015). This results in decreasing of bactericidal activity of leucocyte, and so also decrease the effectiveness of ATA.

As shown in table 1, total of 48% patients had DM as comorbid. DM also can changes some pharmacokinetics profile of ATA. ATA efficacy generally depends on the concentration

of the drug in the plasma where DM had negative effect. The low levels of ATA in plasma will also increase drugs resistance (Mihardja, Lolong, & Ghani, 2015). DM results in the risk of treatment failure, the risk of death, and the relapse of tuberculosis (Baker, et al., 2011). Patients with DM type 2 will develop immune function defects resulting in impaired of protein metabolism, elevated plasma cortisol levels, increased ketone bodies, acidosis, macrophage phagocytosis and decreased humoral immunity (Mihardja, Lolong, & Ghani, 2015). Decreasing the response of humoral immunity will result in a decreased inflammatory response, so ¹⁰ levels of IFN- γ and IL-10 also decrease.

As shows in Figure 2, ¹ serum levels of IFN- γ and IL-10 in the groups 2 are increasing compare to patients in groups 1, eventhough not statistically significant. Group 2 are patients who had converted sputum test results but still in initiation phase of treatment. This may caused by Post Antibiotic Effect (PAE) of some antibiotics. PAE is delaying effect antibiotics to bacterial growth after exposure of antibiotics, or in other words bacterial growth are still depressed despite the concentration of antibiotics already under the MIC (Minimum Inhibition Concebtration). The presence of PAE in OAT therapy provides an wider dose interval without loss of their therapeutic efficacy. Intervals in addition to reducing drug costs and toxicity may also improve patient compliance (Chan, Yeang, Yew, & Hui, 2004). The PAE of the first-line OAT invitro is 6 to 96 hours. PAE invivo is generally longer than PAE invitro for the same drug combination.

As shows in figure 2, ¹ serum levels of IFN- γ and IL-10 in group 3 patients are decreased compare to patients in group 2 eventhought not satatistically significant. Groups3 is patients who were in first 6 months of continuation phase. This group also shows a very widely vary data, this may be because the patient has undergone the therapy for a very long periode. So that patients feel bored and affect the level of adherence of patients o take the drugs, consequently also affect ²⁰ the levels of IFN- γ and IL-10.

As shows in Figure 2, serum levels of IFN- γ and IL-10 in the groups 4 are increasing compare to patients in groups 3, eventhough not statistically significant. Many factors affecting the efficacy of MDR TB therapy and the resistance factor of *Mycobacterium tuberculosis* also result in increasing of IFN- γ and IL-10 a marker of inflammation in the body eventhought not statistically significant. Some confounding factors include nutritional status, resistance factors, comorbid factors, prognose of the disease and another factors also influenceso those results. Also, the samples use in this study in every groups were different patients, so the variability profile of patients in each groups will also influence the results of this study.

As shows in figure 4, the curve IFN- γ and IL-10 serum levels are tends to be plateau. The plateau tendency curve can describe an ongoing inflammatory process, especially in patients with an almost complete continuation phase therapy. In this study, the variation of the measurement result is large enough to get standard deviation, this result in non statistically significant result. Confounding factors such as comorbidity, nutritional status, varying age and adherence may also affect differences in IFN- γ and IL-10 levels. But this study is expected to be a preliminary study for the next pulmonary MDR-TB study or research by providing an overview or condition profile of inflammatory and therapeutic responses of MDR OAT therapy in patients with pulmonary MDR-TB, specifically in Indonesia.

CONCLUSION

Based on IFN- γ , and IL-10 levels in the early and advanced phases as well as next 4 weeks observation after ATA therapy in pulmonary MDR-TB patients showed that there is still an inflammatory process in patients with pulmonary MDR-TB. So it needs further study related to the influence of comfounding factor in MDR lung TB cases such as comorbid, sputum conversion status, drug side effects, resistance occurrence and nutritional status of patients.

REFERENCES

- A. Khan, M. et al., 2015. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. *Saudi Medical Journal*, 36(12), pp. 1463-1471
- Adrian, T. B. R., Montiel, J. L., Fernandez, G. & Valecillo, A., 2015. Role of cytokines and other factors involved in the Mycobacterium tuberculosis infection. *World Journal of Immunology*, 5(1), pp. 16-50.
- Ali Khan, T. et al., 2016. Interferon-Gamma Improves Macrophages Function Against M. Tuberculosis in Multidrug-Resistant Tuberculosis Patients. *Hindawi*, Volume 1-10, p. 2016.
- Antonio, Lemoa, C. M. & Matos, E. D., 2013. Multidrug-resistant tuberculosis, Special article. *The Brazilian Journal of Infections Disease*, Volume 7 (2), p. 239-246.
- Baker, M. A. et al., 2011. The impact of diabetes on tuberculosis treatment Outcomes: A systematic review. *BMC Medicine*, 9(81), pp. 1-15.
- Basit, A. et al., 2014. Predictors of Two Months Culture Conversion in Multidrug-Resistant Tuberculosis: Findings from a Retrospective Cohort Study. *PLOS*, 9(4), pp. 1-6.
- Bowdish DME, et al., 2009. MARCO, Toll Like Receptor 2 (TLR 2), CD14 Are Required for Macrophage Cytokine Response to Mycobacterial Trehalose Dimycolate and Mycobacterium tuberculosis. *Plos Pathog*, Volume 5, p. 6.
- Clifford, V. et al., 2015. Cytokines for monitoring anti-tuberculous therapy: A systematic review. *Elsevier*, Volume XXX, pp. 1-12.
- Crevel, R. V., Tom, H. O. & Jos, W. v. d. M., 2002. Innate Immunity to Mycobacterium tuberculosis. *Clinical microbiology*, 15(2), pp. 294-309.
- Deveci, F., Akbulut, H., Turgut, T. & Muz, H., 2005. Change in Serum Cytokine Levels in Active Tuberculosis With Treatment. *Mediators of Inflammation*, Volume 5, pp. 256-262.
- Fatima, N., Shameem, M. & Nabeela, K. H. M., 2016. Cytokines as Biomarkers in the Diagnosis of MDR TB cases. *Cronocon*, Volume 2.1, pp. 57-61.
- Holtz, T. H. et al., 2006. Time to sputum culture conversion in MDR-TB: Predictor and Relationship to treatment outcome. *Annals of Internal Medicine*, Volume 144, p. 650-660.
- J. -S. LEE, et al., 2002. Profiles of IFN-g and its regulatory cytokines (IL-12, IL-18 and IL-10) in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis. *Clin Exp Immunol*, Volume 128, p. 516-524.
- Jain S, L. G. N. S. P. M. B. W., 2008. Jain S, Lamichhane, Gyanu, Antibiotic Treatment of Tuberculosis: Old Problems. *Microbe*, 3((6)), p. 285.
- Jan, F. et al., 2017. Electrolytes imbalance caused by amikacin in patients receiving multi drug resistance tuberculosis treatment at Hazara region Kpk, Pakistan. *Tuberk Toraks*, 65(3), pp. 193-201.
- Kinjo, Y. et al., 2002. Contribution of IL-18 to Th1 Response and host Defense Against Infection by Mycobacterium tuberculosis: A Comparative Study with IL-12p40. *The Journal of Immunology*, Volume 169, pp. 323-329.
- Kumar, V., Abbas, A. K. & Fausto, N., 2005. *Robbins & Cotran pathologic basis of disease*, 7 ed. New York: Elsevier.
- Laporan, T., 2015. *Laporan Tahunan Poli Paru MDR RSUD dr Soetomo*, s.l.: s.n.
- Mase, S., Chorba, T., Lobue, P. & Castro, K., 2013. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for MDR TB. *MMWR*, Volume 62/No 9, p. 1.
- Mihardja, L., Lolong, B. D. & Ghani, L., 2015. Prevalensi Diabetes Militus Pada Tuberkulosis dan Masalah Terapi. *Jurnal Ekologi Kesehatan*, 14(4), pp. 350-358.
- Mishra, B. B. et al., 2012. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-beta. *Nature immunology*, pp. 1-10.

- Reviono, et al., 2014. Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. *MKB*, 46(4), pp. 189-196.
- Shekar-Abi, M. et al., 2004. The Study of Th1/Th2 Cytokine Profile (IL-10, IL-12, IL-4, and IFN-gamma) in PBMCs of Patients with Multidrug Resistant Tuberculosis and Newly Diagnosed Drug Responsive Cases. *Tanaffos*, 3((10)), pp. 25-31.
- Shin, S. et al., 2004. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. *Clinical Investigasi*, 125(3), pp. 974-980.
- Shin, S. et al., 2007. Adverse reactions among patients being treated for MDT-TB in Tomsk, Russia. *Int J Tuberc Lung Dis*, 11(12), pp. 1314-1320.
- Tan, Q. et al., 2012. Characterization of Th1-and Th2-type immune response in human multidrug-resistant tuberculosis. *Eur J Clin Microbiol Infect Dis*, Volume 31, pp. 1233-1242
- Yong Eum, S. et al., 2008. Tumour Necrosis Factor-alpha and Interleukin 10 in Whole Blood Is Associated with Disease Progression in Pulmonary Multi Drug-Resistant Tuberculosis Patients. *Clinical Investigations*, Volume 76, pp. 331-337.
- Yoshida, A., Inagawa, H. K. C., Nishizawa, T. & Soma, G. c., 2009. The Role of Toll-Reseptor 2 in Survival Strategies of Mycobacterium tuberculosis in macrophage phagosome. *Anticancer Research*, Volume 2009, pp. 907-10

ANALISIS KADAR IFN- γ dan IL-10 SEBAGAI PENANDA INFLAMASI DAN RESPONS TERAPI OBAT ANTI TUBERKULOSIS PASIEN TB PARU MDR

ORIGINALITY REPORT

19%

SIMILARITY INDEX

16%

INTERNET SOURCES

11%

PUBLICATIONS

2%

STUDENT PAPERS

PRIMARY SOURCES

1	repository.unair.ac.id Internet Source	9%
2	Cavalcanti, Yone Vila Nova, Maria Carolina Accioly Brelaz, Juliana Kelle de Andrade Lemoine Neves, José Candido Ferraz, and Valéria Rêgo Alves Pereira. "Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis", Pulmonary Medicine, 2012. Publication	1%
3	link.springer.com Internet Source	1%
4	www.scribd.com Internet Source	<1%
5	www.rbc.org.br Internet Source	<1%
6	Alaa El-Din A. Moubasher, Neveen A. Kamel,	<1%

Hatem Zedan, Diao El-Din Abdel Raheem. " ",
International Journal of Dermatology, 2002

Publication

- 7 Chuchottaworn, Charoen, Vipa Thanachartwet, Piamlarp Sangsayunh, Thu Zar Myint Than, Duangjai Sahassananda, Manoon Surabotsophon, and Varunee Desakorn. "Risk Factors for Multidrug-Resistant Tuberculosis among Patients with Pulmonary Tuberculosis at the Central Chest Institute of Thailand", PLoS ONE, 2015. <1%
- Publication
-

- 8 www.cfnpp.cornell.edu <1%
- Internet Source
-

- 9 edepot.wur.nl <1%
- Internet Source
-

- 10 Thuy Thi Bich Phung, Tadaki Suzuki, Phuc Huu Phan, Shoji Kawachi et al. "Pathogen screening and prognostic factors in children with severe ARDS of pulmonary origin", Pediatric Pulmonology, 2017 <1%
- Publication
-

- 11 Irsitbrd.nic.in <1%
- Internet Source
-

- 12 medicaljournalofcairouniversity.net <1%
- Internet Source
-

13

Kefyalew Addis Alene, Kerri Viney, Emma S. McBryde, Adino Tesfahun Tsegaye, Archie C. A. Clements. "Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia", *Tropical Medicine & International Health*, 2017

Publication

<1%

14

www.jbc.org

Internet Source

<1%

15

www.dovepress.com

Internet Source

<1%

16

nbn-resolving.de

Internet Source

<1%

17

efmaefm.org

Internet Source

<1%

18

M. MIFTAHUSSURUR, S. SHIOTA, R. SUZUKI, M. MATSUDA et al. " Identification of infection in symptomatic patients in Surabaya, Indonesia, using five diagnostic tests ", *Epidemiology and Infection*, 2014

Publication

<1%

19

Antonio Gutiérrez, José Rodríguez, Jordi Martínez, Rocío Amezaga et al. "Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma", *Leukemia & Lymphoma*, 2009

<1%

-
- | | | |
|----|---|-----|
| 20 | www.ejmm.edu.eg
Internet Source | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 21 | Sosroseno, Wihaskoro. "Effect of Sodium Fluoride on the Murine Splenic Immune Response to Porphyromonas gingivalis In Vitro : BRIEF COMMUNICATION", Immunopharmacology and Immunotoxicology, 2003.
Publication | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 22 | edoc.pub
Internet Source | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 23 | www.theautohouse.co.uk
Internet Source | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 24 | garuda.ristekdikti.go.id
Internet Source | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 25 | www.jove.com
Internet Source | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 26 | pt.scribd.com
Internet Source | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 27 | article.ijimmunology.org
Internet Source | <1% |
|----|---|-----|
-
- | | | |
|----|---|-----|
| 28 | "Antimicrobial Drug Resistance", Springer Nature, 2017
Publication | <1% |
|----|---|-----|
-

29

D. A. Vargas-Inchaustegui. "Distinct roles for MyD88 and TLR2 during *Leishmania braziliensis* infection in mice", *Infection and Immunity*, 04/13/2009

Publication

<1%

30

Rachoń, Dominik, Guillermo Rimoldi, and Wolfgang Wuttke. "In Vitro Effects of Benzophenone-2 and Octyl-Methoxycinnamate on the Production of Interferon- γ and Interleukin-10 by Murine Splenocytes", *Immunopharmacology and Immunotoxicology*, 2006.

Publication

<1%

31

Basu, Joyoti, Dong-Min Shin, and Eun-Kyeong Jo. "Mycobacterial signaling through toll-like receptors", *Frontiers in Cellular and Infection Microbiology*, 2012.

Publication

<1%

32

Nada Pitabut, Shinsaku Sakurada, Takahiro Tanaka, Chutharut Ridruechai, Junko Tanuma, Takahiro Aoki, Pacharee Kantipong, Surachai Piyaworawong, Nobuyuki Kobayashi, Panadda Dhepakson, Hideki Yanai, Norio Yamada, Shinichi Oka, Masaji Okada, Srisin Khusmith, Naoto Keicho. "Potential Function of Granulysin, Other Related Effector Molecules and Lymphocyte Subsets in Patients with TB and HIV/TB Coinfection", *International Journal of*

<1%

Medical Sciences, 2013

Publication

Exclude quotes Off

Exclude matches Off

Exclude bibliography On